Skip to main content

Drug Interactions between Evusheld and sars-cov-2(covid-19)mrna(tozinameran 5y-11y)bivalent vaccine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

tixagevimab SARS-CoV-2(COVID-19)mRNA(tozinameran 5y-11y)bivalent vaccine

Applies to: Evusheld (cilgavimab / tixagevimab) and sars-cov-2(covid-19)mrna(tozinameran 5y-11y)bivalent vaccine

The safety, immunogenicity, and efficacy of SARS-CoV-2 (COVID-19) vaccines have not been evaluated during concomitant administration of tixagevimab and cilgavimab. However, no safety concerns were identified in limited data from the PROVENT trial, where patients were able to elect to receive COVID-19 vaccination after administration of tixagevimab and cilgavimab. Additionally, pharmacokinetic modeling did not reveal any clinically relevant impact on the clearance of these anti-SARS-CoV-2 monoclonal antibodies after receipt of a COVID-19 vaccination. The United States Food and Drug Administration (FDA) revised its emergency use authorization for tixagevimab co-packaged with cilgavimab (Evusheld) on January 26, 2023, to limit the use of this product to when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%. Current guidelines should be consulted for recommended timing of vaccination in relation to the administration of tixagevimab and cilgavimab.

References

  1. "Product Information. Evusheld (cilgavimab-tixagevimab)." Astra-Zeneca Pharmaceuticals (2021):
  2. CDC Centers for Disease Control and Prevention "Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html" (2022):
  3. "Product Information. Evusheld (cilgavimab-tixagevimab)." AstraZeneca UK Ltd (2022):
  4. "Product Information. Evusheld (cilgavimab-tixagevimab)." AstraZeneca Pty Ltd (2023):
  5. "Product Information. Evusheld (cilgavimab-tixagevimab)." AstraZeneca Canada Inc 2.0 (2023):
  6. FDA. United States Food and Drug Administration "FDA announces Evusheld is not currently authorized for emergency use in the U.S. https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us" (2023):
View all 6 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer